Compare PEG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEG | INSM |
|---|---|---|
| Founded | 1903 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | PEG | INSM |
|---|---|---|
| Price | $79.08 | $195.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | $92.25 | ★ $180.94 |
| AVG Volume (30 Days) | 2.7M | ★ 2.8M |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 2.23 | N/A |
| EPS | ★ 4.16 | N/A |
| Revenue | ★ $11,718,000,000.00 | $447,022,000.00 |
| Revenue This Year | $19.75 | $43.10 |
| Revenue Next Year | $2.67 | $128.25 |
| P/E Ratio | $18.98 | ★ N/A |
| Revenue Growth | 12.35 | ★ 30.34 |
| 52 Week Low | $74.67 | $60.40 |
| 52 Week High | $91.26 | $212.75 |
| Indicator | PEG | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 50.33 |
| Support Level | $77.90 | $189.59 |
| Resistance Level | $80.52 | $206.69 |
| Average True Range (ATR) | 1.28 | 6.43 |
| MACD | -0.32 | -3.01 |
| Stochastic Oscillator | 20.10 | 23.53 |
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plans and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.